Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price dropped 26.7% on Tuesday. The stock traded as low as C$0.06 and last traded at C$0.06. Approximately 241,949 shares traded hands during mid-day trading, an increase of 453% from the average session volume of 43,775 shares. The stock had previously closed at C$0.07.
Hemostemix Stock Performance
The company has a quick ratio of 0.48, a current ratio of 0.13 and a debt-to-equity ratio of -61.85. The company has a market cap of C$11.63 million, a PE ratio of -2.12 and a beta of 0.50. The business’s fifty day moving average is C$0.07 and its 200-day moving average is C$0.06.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Recommended Stories
- Five stocks we like better than Hemostemix
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
